Compare EVTL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTL | RNA |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United Kingdom | United States |
| Employees | 454 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.6M | 222.5M |
| IPO Year | N/A | 2025 |
| Metric | EVTL | RNA |
|---|---|---|
| Price | $0.90 | $12.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 20 |
| Target Price | $12.70 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 2.2M | 117.7K |
| Earning Date | 03-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | N/A | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $11.13 |
| 52 Week High | $7.35 | $73.06 |
| Indicator | EVTL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 53.09 |
| Support Level | N/A | $11.95 |
| Resistance Level | $1.79 | $14.05 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 12.83 | 82.66 |
Vertical Aerospace Ltd is engaged in making air travel personal, on-demand, and carbon-free. The company is a world-wide aerospace and technology company that is pioneering electric aviation, focused on designing, manufacturing, and selling a zero-emission eVTOL aircraft for use in the AAM market, using the technology from the aerospace, automotive, and energy industries. The VX4, Vertical's flagship aircraft, is a piloted electric vertical take-off and landing (eVTOL) vehicle capable of carrying four passengers. The Group operates as a single operating segment and one reporting segment, being the development and commercialization of eVTOL technology.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.